Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
An update from Recce Pharmaceuticals Ltd. ( (AU:RCE) ) is now available.
Recce Pharmaceuticals Ltd has announced its Annual General Meeting scheduled for November 5, 2025, with the closing date for director nominations set for September 23, 2025. This announcement underscores the company’s ongoing commitment to advancing its anti-infective pipeline, which has garnered significant attention from global health authorities for its potential to address critical health challenges posed by resistant pathogens.
The most recent analyst rating on (AU:RCE) stock is a Hold with a A$0.50 price target. To see the full list of analyst forecasts on Recce Pharmaceuticals Ltd. stock, see the AU:RCE Stock Forecast page.
More about Recce Pharmaceuticals Ltd.
Recce Pharmaceuticals Ltd is a company focused on developing a new class of synthetic anti-infectives aimed at combating antibiotic-resistant superbugs and emerging viral pathogens. Their product pipeline includes patented, broad-spectrum synthetic polymer anti-infectives such as RECCE 327, RECCE 435, and RECCE 529, which target serious bacterial and viral infections. The company has received recognition from the World Health Organization and the FDA for its innovative efforts in addressing antimicrobial resistance.
Average Trading Volume: 126,060
Technical Sentiment Signal: Hold
Current Market Cap: A$118.6M
For detailed information about RCE stock, go to TipRanks’ Stock Analysis page.